Amgen says 'breakthrough' drug improves lung cancer survival by 58% The Independent 10:15 Sun, 25 Oct The Independent 10:15 Sun, 25 Oct Pharma Cutting Edge Biotech Article paywall
Amgen vs. Bristol Myers Squibb: Which healthcare stock is a better buy in 2026? The Motley Fool 23:11 Tue, 20 Oct The Motley Fool 23:11 Tue, 20 Oct Bristol Myers Squibb Biotechnology Pharma
Amgen drug combined with immunotherapy extends survival in lung cancer trial The Hindu 05:06 Tue, 27 Oct The Hindu 05:06 Tue, 27 Oct Pharma Biotech Article paywall
Amgen vs. Johnson & Johnson: Which healthcare giant has the better stock to buy? The Motley Fool 17:37 Sat, 24 Oct The Motley Fool 17:37 Sat, 24 Oct Johnson and Johnson Biotechnology Pharma
Amgen’s Repatha reduces heart attack risk in real-world study Clinical Trials Arena 2d Clinical Trials Arena 2d Pharma Biotech
Repatha Linked to 20% Lower Heart Attack Rate Than Ezetimibe in 544,000-Patient Study Medical Daily 17:50 Sat, 07 Nov
Amgen (AMGN) Stock Could Be 34% Below Fair Value Following Raised Guidance Simply Wall St 11:37 Sat, 07 Nov
Amgen’s Repatha reduces heart attack risk in real-world study Clinical Trials Arena 11:30 Fri, 06 Nov
Repatha® Lowers Risk Of Heart Attacks By 20% Compared With Ezetimibe In A Large Real-World Study Amgen (Press Release) 14:06 Thu, 05 Nov
Amgen Sees Big Sales Growth But Multiple Products Face Threats Scrip Pharma Intelligence 00:30 Wed, 04 Nov
Looking For Growth, Income, and Stability? This Stock Could Offer All 3 The Motley Fool 17:22 Sat, 31 Oct